Bristol Myers Squibb and 2seventy Bio's Abecma Trial Halt in Newly Diagnosed Myeloma Patients

Wednesday, 25 September 2024, 08:56

Bristol Myers Squibb and 2seventy Bio have halted the Phase 3 KarMMa-9 trial for Abecma in newly diagnosed myeloma patients. This decision forecasts saving of $80 million as the companies shift focus toward profitability by 2025, anticipating strong growth post-FDA approval.
Benzinga
Bristol Myers Squibb and 2seventy Bio's Abecma Trial Halt in Newly Diagnosed Myeloma Patients

Bristol Myers Squibb and 2seventy Bio's Decision

In a noteworthy strategic shift, Bristol Myers Squibb and 2seventy Bio have decided to halt the Phase 3 KarMMa-9 trial for Abecma in newly diagnosed myeloma patients. This significant move is aimed at saving $80 million, allowing the companies to focus on profitability by 2025.

Future Implications for Abecma

Despite this decision, the companies are optimistic about strong growth, particularly following the FDA approval received in April. The halt in the clinical trial could reshape the strategic approach towards myeloma treatments as both companies aim to optimize resources and drive profitability.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the most accurate and current medical news. Stay updated and deepen your understanding of medical advancements effortlessly.

Subscribe